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Abstract
Introduction
We assessed the cost-effectiveness of a community-based, 
modified Diabetes Prevention Program (DPP) designed to 
reduce risk factors for type 2 diabetes and cardiovascular 
disease.
Methods
We  developed  a  Markov  decision  model  to  compare 
costs  and  effectiveness  of  a  modified  DPP  intervention 
with usual care during a 3-year period. Input parameters 
included costs and outcomes from 2 projects that imple-
mented  a  community-based  modified  DPP  for  partici-
pants with metabolic syndrome, and from other sources. 
The  model  discounted  future  costs  and  benefits  by  3%   
annually.
Results
At 12 months, usual care reduced relative risk of meta-
bolic  syndrome  by  12.1%.  A  modified  DPP  intervention 
reduced relative risk by 16.2% and yielded life expectancy 
gains of 0.01 quality-adjusted life-years (3.67 days) at an 
incremental  cost  of  $34.50  ($3,420  per  quality-adjusted 
life-year  gained).  In  1-way  sensitivity  analyses,  results 
were sensitive to probabilities that risk factors would be 
reduced with or without a modified DPP and that patients 
would  enroll  in  an  intervention,  undergo  testing,  and 
acquire diabetes with or without an intervention if they 
were  risk-factor–positive.  Results  were  also  sensitive  to 
utilities  for  risk-factor–positive  patients.  In  probabilis-
tic  sensitivity  analysis,  the  intervention  cost  less  than 
$20,000 per quality-adjusted life-year gained in approxi-
mately 78% of model iterations.
Conclusion
We consider the modified DPP delivered in community 
and primary care settings a sound investment.
Introduction
Randomized  controlled  trials  have  demonstrated  the 
efficacy  of  lifestyle  interventions  aimed  at  preventing 
or delaying onset of type 2 diabetes (1-4). The Diabetes 
Prevention Program (DPP) found that either medication or 
intensive lifestyle interventions could prevent progression 
from impaired glucose tolerance to diabetes (1). This ran-
domized controlled trial provided study participants with 
individualized, resource-intensive management and over-
sight (5). During the 3 years of the DPP, diet and exercise 
reduced the risk that patients with impaired glucose toler-
ance would develop diabetes by 58% (1). These outcomes 
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the 
Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only and 
does not imply endorsement by any of the groups named above.
  www.cdc.gov/pcd/issues/2010/sep/09_0200.htm • Centers for Disease Control and Prevention  1
Cost-Effectiveness Analysis of Efforts 
to Reduce Risk of Type 2 Diabetes and 
Cardiovascular Disease in Southwestern 
Pennsylvania, 2005-2007
ORIGINAL RESEARCH
Kenneth J. Smith, MD, MSc; Heather E. Hsu, MPH; Mark S. Roberts, MD, MPP; M. Kaye Kramer, DrPH, BSN; 
Trevor J. Orchard, MD; Gretchen A. Piatt, PhD; Miriam C. Seidel, MS, RD; Janice C. Zgibor, PhD; Cindy L. Bryce, PhDVOLUME 7: NO. 5
SEPTEMBER 2010
2  Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2010/sep/09_0200.htm
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the 
Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only and 
does not imply endorsement by any of the groups named above.
appear sustainable given follow-up data from the Da Qing 
Diabetes Prevention Study (6) and the Finnish Diabetes 
Prevention Study (7). Unfortunately, such programs can 
be expensive to implement and can exclude people with 
some comorbidities, who may benefit from even modest 
improvements in diet and physical activity.
Community-based lifestyle interventions adapted from 
the DPP (1) demonstrate effectiveness for improving the 
risk factors for diabetes in community settings (8-10), but 
their costs are largely unexplored. US cost-effectiveness 
studies of intensive lifestyle interventions to prevent dia-
betes have differed in their perspectives, time frames, and 
inclusion of prediabetes screening costs, producing cost-
effectiveness  ratios  that  range  from  $1,100  to  $143,000 
per  quality-adjusted  life-year  (QALY)  (11-13).  However, 
intervention efficacy and cost data for these studies were 
largely  based  on  the  intensive  strategies  and  resources 
used by the original DPP (14,15).
The  Diabetes  Prevention  Support  Center  of  the 
University of Pittsburgh Diabetes Institute developed a 
modified version of the DPP lifestyle intervention (mDPP) 
and tested its effectiveness in the community and local 
medical practice settings with patients at increased risk 
of  diabetes  or  cardiovascular  disease  (CVD)  (8,16).  We 
assessed cost-effectiveness of this mDPP.
Methods
Study population
Diabetes Prevention Support Center faculty developed 
the Group Lifestyle Balance program by translating the 
original DPP lifestyle intervention (14) for distinct popula-
tions and measuring program effects in those populations. 
Intervention goals were to help patients with metabolic 
syndrome lose weight and improve at least 1 metabolic 
syndrome component. Investigators evaluated this inter-
vention in different populations in 2 studies. In the first 
study,  investigators  assessed  intervention  effectiveness 
in 2 urban and 2 rural medical practices in southwestern 
Pennsylvania  (16).  They  screened  and  recruited  par-
ticipants  through  the  practices  and  hired  trained  pre-
ventionists who were health care professionals to deliver 
the  program.  The  second  study  was  a  nonrandomized 
prospective trial to test intervention effectiveness in an 
urban, medically underserved community (8). The study 
held  community-based  screenings  in  targeted  neighbor-
hoods to identify and recruit eligible subjects, and a team 
of 2 health professionals and 2 lay health workers sched-
uled the lifestyle intervention sessions at worksites and 
churches.
Group Lifestyle Balance adapted the original DPP for 
use  in  group-based  settings  rather  than  individualized 
delivery  and  decreased  the  number  of  lessons  from  16 
to 12, offered for 12 to 14 weeks. Sessions were designed 
to achieve and maintain a 5% to 7% weight loss and to 
progressively  raise  activity  levels  to  150  minutes  per 
week of moderately intense physical activity. Both stud-
ies assessed subjects for excess weight (body mass index 
[BMI] ≥25 kg/m2) and the following 4 components of meta-
bolic  syndrome,  as  defined  by  the  National  Cholesterol 
Education  Program’s  Adult  Treatment  Panel  III  (17): 
waist  circumference  (>102  cm  for  men  and  >88  cm  for 
women), high-density lipoprotein cholesterol (<40 mg/dL 
for men and <50 mg/dL for women), fasting glucose (≥100 
mg/dL), and blood pressure (≥130/85 mm Hg). In addition, 
1 study screened for triglyceride levels (≥150 mg/dL) (8).
Development of a decision model
We  used  TreeAge  Decision  Pro  Suite  2008  (TreeAge 
Software, Inc, Williamstown, Massachusetts) to construct 
a Markov decision model to estimate the incremental cost-
effectiveness of a community-based mDPP. In the model, 
we used a base case that examined 55-year-old men and 
women at monthly intervals for 3 years. This time frame 
was chosen to limit projections regarding the continuing 
effectiveness of the mDPP, which is unknown; differing 
mDPP  effectiveness  assumptions  over  time  were  exam-
ined in sensitivity analyses. We defined the incremental 
cost-effectiveness as the additional cost of using an mDPP 
compared with providing usual care, divided by the addi-
tional clinical benefit of using the mDPP compared with 
providing  usual  care.  For  this  model,  usual  care  is  the 
absence of a screening program and intervention.
In keeping with the reference case recommendations of 
the Panel on Cost-Effectiveness in Health and Medicine 
(18), we discounted future costs and benefits by 3% annu-
ally. We used a modified societal perspective in which the 
costs of patients’ time were not included. To convert all 
monetary costs to the US dollar rate for 2000, we used the 
US Consumer Price Index. To account for changes in life 
expectancy and quality of life for diabetes-related health VOLUME 7: NO. 5
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states, we used QALYs, which adjust for quality based on 
a utility weight, or preference, for the health state ranging 
from 0 (death, least preferred) to 1 (perfect health, most 
preferred).
Clinical outcomes and costs related to diabetes and com-
plicated diabetes for both the mDPP and usual care were 
derived  from  the  DPP  (12,19),  the  Framingham  Heart 
Study (20), and the United Kingdom Prospective Diabetes 
Study (12,21,22). Program costs, recruitment and reten-
tion rates, patient demographics, and program effective-
ness were derived from the 2 community-based studies. 
mDPP costs were the costs of screening plus the personnel 
costs per patient  (Table).
Basic model structure
To analyze the cost-effectiveness of an mDPP, we used 
the Markov model (Figure 1). At the start, subjects with-
out a history of diabetes are evaluated once for risk factors 
for diabetes and CVD. Subjects are considered to be risk-
factor–positive  if  they  are  overweight  (BMI  ≥25  kg/m2) 
and have at least 3 components of metabolic syndrome. 
They are also considered to be risk-factor–positive if they 
are overweight, have at least 2 components of metabolic 
syndrome, have a fasting glucose level of 100 mg/dL to 109 
mg/dL, and have a physician referral to the intervention. 
They are considered to be risk-factor–negative if they do 
not meet either of these sets of criteria.
In the model, risk-factor–positive subjects are eligible 
for  mDPP  enrollment.  Those  enrolling  in  the  program 
show metabolic syndrome resolution at rates found in the 
mDPP interventions during the first year of the model. 
Participants who begin the program but do not return for 
the 12-month follow-up are considered nonenrolled, thus 
accounting for withdrawal from the program. Those who 
do not enroll show a resolution of metabolic syndrome at 
the rate reported for the placebo arm of the DPP (19) dur-
ing the 3 years of the model; this same rate of reduction 
is used for enrolled patients during model years 2 and 3 
in the base case analysis. In sensitivity analyses, we also 
examined other assumptions for continued resolution of 
metabolic  syndrome:  1)  no  further  resolution  after  the 
first year for enrolled and nonenrolled patients and 2) no 
further resolution after the first year for enrolled patients 
but continued metabolic syndrome resolution at DPP pla-
cebo rates for all 3 model years in nonenrolled patients. 
Risk-factor–negative patients are ineligible for enrollment 
in the mDPP, and they develop metabolic syndrome at the 
rate reported for the placebo arm of the DPP (19).
Both  risk-factor–positive  and  risk-factor–negative 
patients  are  at  risk  for  developing  diabetes  at  rates 
reported by the DPP. In patients who develop diabetes, the 
transition to complicated diabetes is preceded by a stable 
diabetes stage. Complications from diabetes include neu-
ropathy, nephropathy, stroke, and coronary heart disease. 
In the model, patients in all health states can die; rates 
of death are based on age- and sex-specific US mortality 
(which accounts for baseline mortality) and the relative 
risks of death for metabolic syndrome, stable diabetes, and 
complicated diabetes (30).
Sensitivity analyses
We  performed  1-way  sensitivity  analyses  and  proba-
bilistic  sensitivity  analyses  on  model  input  parameters. 
In  these  analyses,  the  parameters  (Table)  were  varied 
either individually or collectively over their listed ranges, 
with  1,000  recalculations  of  incremental  cost-effective-
ness ratios based on random draws from the parameter 
Figure 1. Model analyzing cost-effectiveness of a modified Diabetes 
Prevention Program (mDPP), southwestern Pennsylvania, 2005-2007. Ovals 
indicate health states. Subjects may remain in a health state (short curved 
arrow) or may move to a different health state (straight arrow or long curved 
arrow) during each model cycle.VOLUME 7: NO. 5
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distributions. Generally, without precise empirical data, 
sensitivity analyses rely on parameter distributions that 
reflect uncertainty and the range of likely values. In our 
analyses, cost data and utilities were varied over uniform 
distributions. Incidence and prevalence parameters were 
varied over beta distributions, relative risks were varied 
over log-normal distributions, and cost multipliers were 
varied over normal distributions.
The University of Pittsburgh institutional review board 
approved the protocols of both intervention studies and 
the  cost-effectiveness  analyses,  and  study  participants 
provided informed consent.
Results
By the 12-month point in the model, the mDPP inter-
vention  reduced  metabolic  syndrome  risk  at  1  year  by 
16.2% (compared with usual care, which reduced the risk 
of metabolic syndrome by 12.1%). During the 3-year time 
frame  of  the  model,  both  costs  and  effectiveness  of  the 
mDPP were slightly higher than usual care. The mDPP 
costs totaled $2,528 (compared with $2,493 for usual care) 
and the effectiveness of the mDPP equaled 2.40 QALYs 
(compared with 2.39 QALYs for usual care). Taken togeth-
er,  the  mDPP  gained  0.01  QALYs  (approximately  3.67 
days) at an incremental cost of $34.50, equal to an incre-
mental cost-effectiveness ratio of $3,420 per QALY. These 
results were due mainly to decreases in diabetes incidence 
with the mDPP. Without the mDPP, 9.6% of the cohort 
developed  diabetes  over  3  years;  with  the  mDPP,  7.7% 
did. Over this period, little difference between groups was 
seen (1.1% vs 0.9%) in diabetes complication incidence, as 
broadly defined by the DPP.
In 1-way sensitivity analyses, results were most sensi-
tive to changes in risk-factor reduction with or without the 
mDPP, intervention rates, risk-factor–positive screening 
rates,  and  diabetes  incidence  rates  in  risk-factor–posi-
tive people with or without an intervention. Results were 
also sensitive to utilities for risk-factor–positive patients 
(Figure 2).
When base case values were used for all parameters, an 
mDPP intervention cost $3,420 per QALY. When param-
eters were varied to the extremes of the ranges shown 
in  the  Table,  the  cost-effectiveness  ratio  remained  less 
than $20,000 per QALY. The cost-effectiveness ratio rose   
highest,  $18,600  per  QALY,  when  the  probability  of 
reducing risk factors in the absence of an mDPP interven-
tion was increased from 12.1% in the base case to 25.9% 
(Figure 2). In addition, the cost-effectiveness of the mDPP 
intervention remained less than $17,000 per QALY when 
the proportion of patients who screen positive for risk fac-
tors increased to 63.5% (base 31%), when the proportion 
of risk-factor–positive patients who enroll in the interven-
tion increased to 86.7% (base 47.0%), when the probability 
of risk-factor reduction increased to 34.4% (base 16.2%), 
and when the relative risk of diabetes given risk factor 
positivity  with  or  without  an  mDPP  decreased  by  two-
thirds. When all other parameters listed in the Table were 
varied in 1-way sensitivity analyses across their specified 
ranges, the cost-effectiveness ratio did not exceed $7,000 
per QALY. Thus, results favoring the mDPP were stable 
to variations in risk-factor reduction and diabetes risks 
that might be seen in differing populations. Varying the 
discount rate for costs and effectiveness (base 3%) from 0% 
to 5% changed model results by less than $400 per QALY 
gained because of the brief 3-year span of the model.
In a  separate  sensitivity  analysis  examining  differing 
assumptions  for  metabolic  syndrome  reduction,  if  we 
assume no reduction in metabolic syndrome for enrolled or 
nonenrolled patients after model year 1, the cost-effective-
ness ratio of the intervention increased slightly, to $3,400 
per  QALY  gained.  If  enrolled  patients  have  no  further 
Figure 2. One-way sensitivity analyses assessing cost-effectiveness of a 
modified Diabetes Prevention Program (mDPP), southwestern Pennsylvania, 
2005-2007. Horizontal bars depict the range of cost-effectiveness ratios 
for the values shown for each parameter. The vertical dotted line depicts 
the base case cost-effectiveness ratio. Variation of all other parameters 
not shown in the figure did not increase the cost-effectiveness ratio above 
$7,000 per quality-adjusted life-year (QALY) gained. VOLUME 7: NO. 5
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reduction in metabolic syndrome after the first year but 
nonenrolled patients continue metabolic syndrome reduc-
tion through the 3 years at rates seen in the DPP placebo 
arm, the intervention would cost $7,270 per QALY.
In a probabilistic sensitivity analysis, when all param-
eters  were  varied  simultaneously  across  their  ranges, 
the mDPP intervention cost less than $20,000 per QALY 
gained  in  approximately  78%  of  model  iterations  and 
less  than  $50,000  per  QALY  in  approximately  86%  of 
iterations (Figure 3). This analysis assumed independence 
among parameter values and did not account for covari-
ance between parameters, which tends to broaden result 
ranges. Thus, we may have underestimated the probabili-
ties.
When the utility weight for risk-factor–positive patients 
not enrolled in an intervention (ie, receiving usual care) 
was set equal to the utility weight for patients enrolled 
in  an  mDPP,  the  mDPP  intervention  cost  $8,300  per 
QALY and yielded life expectancy gains of 0.004 QALYs 
(approximately 1.63 days) for enrollees. We also examined 
scenarios using sets of parameter values unfavorable to 
the  mDPP  intervention.  If  we  simultaneously  assume 
no utility differences with risk factors between interven-
tion groups (as above), a 9.8% diabetes risk on the mDPP 
(so that the risk is only slightly better than the 10.8% 
risk of no mDPP), and a utility of 0.77 with no risk fac-
tors (instead of a low value of 0.84), then the mDPP cost 
$56,200 per QALY gained. If we add to this scenario a 
decrease in mDPP-related benefit (from 16.2% to 14.1%, 
a 2 percentage point difference compared with no mDPP), 
then the mDPP cost $95,400 per QALY.
Discussion
The mDPP was designed to teach groups of people how 
to change their diet and lifestyle to reduce their risk for 
diabetes  and  CVD.  When  we  examined  the  costs  and 
effects of implementing the mDPP intervention in a com-
munity setting, we found that at 12-month follow-up the 
mDPP reduced the relative risk of metabolic syndrome by 
16.2% and yielded a life-expectancy gain of 3.67 days at 
a cost of $3,420 per QALY gained. Even when we varied 
parameter values in sensitivity analyses, the cost-effective-
ness ratio remained less than $20,000 per QALY. Ratios 
less  than  $20,000  are  generally  considered  to  provide 
strong evidence in favor of adopting an intervention (31).
In  analyzing  the  mDPP,  we  used  several  conserva-
tive  practices  and  assumptions  that  would  be  expected 
to negatively bias our findings. First, we used outcome 
parameters  based  on  data  from  real-world  mDPPs  in 
which  participation  ranged  from  attending  1  session  to 
attending  12  sessions  (mean,  8.9  sessions;  median,  10 
sessions).  In  contrast  to  usual  study  designs,  in  which 
attrition and dropout rates are final states (ie, patients do 
not return after dropping out), our study design included 
patients  who  skipped  sessions  throughout  the  12-week 
course. Second, our design was based on an intent-to-treat 
analysis in which all patients who attended at least 1 ses-
sion were included and any patient who did not return 
for the 12-month follow-up was assumed to be risk-fac-
tor–positive even if the 3-month data indicated resolution 
in the patient’s metabolic syndrome. Third, we modeled 
the effects of the intervention over a 3-year time frame. 
If the effects are actually sustained beyond 3 years, as 
other studies suggest (6,12), then our modeling approach 
underestimates the cost-effectiveness of the intervention. 
Given the short time frame of our analysis, the factors that 
contributed  the  most  to  intervention  effectiveness  were 
the changes in quality of life that are due to avoidance of 
diabetes and its complications. Over longer time frames, 
other factors could have a greater impact.
Our study has 2 limitations that deserve mention. First, 
we  used  costs  in  2000  US  dollars.  This  decision  might 
Figure 3. Probabilistic (Monte Carlo) sensitivity analyses assessing cost-
effectiveness of a modified Diabetes Prevention Program (mDPP), south-
western Pennsylvania, 2005-2007. The acceptability curve depicts the 
likelihood of an mDPP lifestyle intervention being favored for a given cost-
effectiveness ceiling threshold (willingness to pay). VOLUME 7: NO. 5
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underestimate the costs of providing the mDPP interven-
tion and usual care today, but it would not be expected to 
greatly underestimate the costs of the mDPP intervention 
relative to the costs of usual care in any particular year. 
Moreover, the choice of base year would not be expected 
to influence the criteria for cost-effectiveness (31). Second, 
as with any modeling exercise, we imposed several sim-
plifications.  For  example,  although  the  probabilities  of 
acquiring  diabetes,  progressing  to  complicated  diabetes, 
and dying of diabetes or other causes depend on a large 
number of covariates, we included only the most common 
covariates. Addressing these limitations would require the 
performance of a large-scale trial to compare the mDPP 
intervention with usual care for a long follow-up period. In 
the absence of such a trial, we believe that using the con-
trol arm of the original DPP as the comparison cohort for 
the mDPP intervention was a reasonable alternative.
Both  the  original  DPP  and  the  mDPP  provide  study 
participants  with  instructions  about  diet  and  physical 
activity.  The  main  difference  is  that  the  DPP  provides 
individualized  instruction  to  participants  with  specific 
types of comorbidities, whereas the mDPP provides group 
instruction and can be applied to participants with a larger 
range of comorbidities. Although the DPP was found to be 
economically reasonable (12), it is more expensive than the 
mDPP and its complexity and rigor make it more difficult 
for medical practitioners to fully implement. The mDPP 
is simpler and less time-consuming to implement. When 
delivered in community and primary care settings, it is 
cost-effective and appears to be a sound investment.
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Table
Table. Base Case Values for Decision Model and Ranges Examined in Sensitivity Analyses of Efforts to Reduce Risk of Type 2 
Diabetes and Cardiovascular Disease, Southwestern Pennsylvania, 2005-2007
Parameter
Base Case 
Value
Type of 
Distribution Range Examined Reference
Cohort characteristics
Starting age, y 55 Uniform 5–5 Assumption
Women, % 75 Beta .2-9.0 mDPP data (,1)
African American, % 27.1 Beta .5-55. mDPP data (,1)
Angina, % . Beta 1.0-. mDPP data (,1)
Hypertension, treated, % .9 Beta .5-100 mDPP data (,1)
History of cardiac arrest or MI, % 1.9 Beta 0.5-.2 mDPP data (,1)
History of stroke, % 1.9 Beta 0.5-.2 mDPP data (,1)
Peripheral vascular disease, % .7 Beta 1.-10.2 mDPP data (,1)
Probabilities, %
Probability of screening risk-factor–positive 1.0 Beta 7.2-.5 mDPP data (,1)
Probability of enrollment 7.0 Beta 9.2-.7 mDPP data (,1)
Yearly probability of acquiring diabetes, %
Not in prevention program, risk-factor–positive 10. Beta 2.9-2. Herman et al (12)
Not in prevention program, risk-factor–negative 0. Beta 0.05-0.75 Fox et al (20)
In prevention program . Beta 1.-10.5 Herman et al (12)
Yearly probability of becoming risk-factor–posi-
tive
.0 Beta 1.0-.7 Orchard et al (19)
Yearly probability of progressing to complicated 
diabetes
7.5 Beta 2.0-1. Herman et al (12), Kothari et al (21), 
Wilson et al (22)
Yearly probability of reducing risk factors, %
Not in prevention program 12.1 Beta .2-25.9 Orchard et al (19)
In prevention program 1.2 Beta .2-. mDPP data (,1)
Relative risk of death
Risk-factor–positive 1.7 Log-normal 1.5-1. Lakka et al (2)
Risk-factor–negative 1.0 NA Not varied Assumption
Stable diabetes 2.0 Log-normal 1.-2.2 Moss et al (2)
Complicated diabetes 2. Log-normal 2.2-2. Fuller et al (25)
 
Abbreviations: mDPP, modified Diabetes Prevention Program; MI, myocardial infarction; NA, not applicable; MEPS, Medical Expenditure Panel Survey. 
a The yearly cost for risk-factor–negative ($1) was computed using the subset of MEPS respondents who had incurred health care expenses during the year 
and who reported a perceived health status of good, very good, or excellent (29).
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Parameter
Base Case 
Value
Type of 
Distribution Range Examined Reference
Utilities
No diabetes, risk-factor–positive, not in preven-
tion program
0.7 Uniform 0.71-0.75 Herman et al (12), Coffey et al (2)
No diabetes, risk-factor–positive, in prevention 
program
0.75 Uniform 0.7-0.77 Herman et al (12), Coffey et al (2)
No diabetes, risk-factor–negative 0. Uniform 0.-0.92 Gold et al (27)
Stable diabetes 0.9 Uniform 0.-0.72 Herman et al (12), Coffey et al (27), Zhou 
et al (2)
Complicated diabetes 0.59 Uniform 0.51-0. Herman et al (12), Coffey et al (27), Zhou 
et al (2)
Costs and multipliers
Screening, risk-factor–positive, $ 5 Uniform 1-5 mDPP data (,1)
Screening, risk-factor–negative, $ 2 Uniform 1- mDPP data (,1)
Prevention program, $ 219 Uniform 110-29 mDPP data (,1)
Risk-factor–positive (yearly), $ 1,29 NA Not varied Herman et al (12)
  Multiplier for female 1.1 Normal 1.05-1.25 Herman et al (12)
  Multiplier for African American 0.2 Normal 0.70-0.95 Herman et al (12)
Risk-factor–negative (yearly), $ 1  NA Not varied MEPSa
Base diabetes cost (yearly), $ 1, NA  Not varied Herman et al (12)
  Multiplier for female 1.25 Normal 1.1-1.5 Herman et al (12)
  Multiplier for African American 0.2 Normal 0.70-0.95 Herman et al (12)
Base complicated diabetes cost (yearly), $ 1, NA  Not varied Herman et al (12)
  Multiplier for female 1.25 Normal 1.1-1.5 Herman et al (12)
  Multiplier for African American 0.2 Normal 0.70-0.95 Herman et al (12)
  Multiplier for angina 1.7 Normal 1.1-2.1 Herman et al (12)
  Multiplier for hypertension, treated 1.2 Normal 1.10-1.7 Herman et al (12)
  Multiplier for history of cardiac arrest or MI 1.90 Normal 1.-2.17 Herman et al (12)
  Multiplier for history of stroke 1.0 Normal 1.20-1.0 Herman et al (12)
  Multiplier for peripheral vascular disease 1.1 Normal 1.10-1.5 Herman et al (12)
 
Abbreviations: mDPP, modified Diabetes Prevention Program; MI, myocardial infarction; NA, not applicable; MEPS, Medical Expenditure Panel Survey. 
a The yearly cost for risk-factor–negative ($1) was computed using the subset of MEPS respondents who had incurred health care expenses during the year 
and who reported a perceived health status of good, very good, or excellent (29).
Table. (continued) Base Case Values for Decision Model and Ranges Examined in Sensitivity Analyses of Efforts to Reduce 
Risk of Type 2 Diabetes and Cardiovascular Disease, Southwestern Pennsylvania, 2005-2007